Table 3:

Cox proportional hazards analysis of progression-free survival for the 220 evaluable patients treated with FAS

Variable	HR	95% CI	P value
Age (>55 vs ≤55 years)	0.86	0.63–1.16	0.307
Sex (male vs female)	0.99	0.72–1.34	0.932
Race (white vs other)	2.6	0.95–2.72	0.078
Stage (metastatic vs locally advanced)	0.74	0.42–1.31	0.30
Functional status (no vs yes)	1.47	0.86–2.50	0.15
Resected primary (yes vs no)	0.897	0.61–1.31	0.57
Line of therapy (≥2nd line vs 1st line)	2.106	1.29–3.16	0.002
Chromogranin A (normal vs elevated)	0.799	0.57–1.14	0.20

HR: hazard ratio; CI: confidence interval